Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK228 and paclitaxel in advanced ovarian cancer
NCT03648489Phase 2Completed
- Sponsor
- Imperial College London
- Start
- Sep 2018
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of sapanisertib in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Imperial College London. Started Sep 2018; status: completed.
02
Drugs
sapanisertib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT03648489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03648489.